The injection has been approved for the treatment of lung, hepatic, colon, prostate, and esophageal cancer via inhibiting tumor cell mitosis at the boundary of the G2/M phase and inducing apoptosis through activation of the Fas/FasL pathway. This evidence concerns the gene FASLG and esophageal cancer.